retatrutide companies Triple Agonist (GLP-1/GIP/GCG) Eli Lilly infiltrates anti-obesity market

Why protein intake drops on GLP-1 When appetite is lower, large high-protein meals can feel difficult to finish

Peptides & Weight Loss at Stillwater Wellness

Call us at 301-250-1196 now to explore the best medical weight loss clinic offering Ozempic and Mounjaro near Silver Spring, MD.

We explore the implications for the food, agribusiness and beverage (FAB) sector

Not sourced from unregulated or overseas suppliers

Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution